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Abstract
 
We have previously reported that hepatitis B virus (HBV)–specific CD8
 
1
 
 cytotoxic T lympho-
cytes and CD4
 
1
 
 helper T lymphocytes can inhibit HBV replication in the liver of HBV trans-
 
genic mice by secreting interferon (IFN)-
 
g
 
 when they recognize viral antigen. To determine
whether an activated innate immune system can also inhibit HBV replication, in this study we
activated natural killer T (NKT) cells in the liver of HBV transgenic mice by a single injection
of 
 
a
 
-galactosylceramide (
 
a
 
-GalCer), a glycolipid antigen presented to V
 
a
 
14
 
1
 
NK1.1
 
1
 
 T cells
by the nonclassical major histocompatibility complex class I–like molecule CD1d. Within 24 h
of 
 
a
 
-GalCer injection, IFN-
 
g
 
 and IFN-
 
a
 
/
 
b
 
 were detected in the liver of HBV transgenic
mice and HBV replication was abolished. Both of these events were temporally associated with
the rapid disappearance of NKT cells from the liver, presumably reflecting activation-induced
cell death, and by the recruitment of activated NK cells into the organ. In addition, prior anti-
body-mediated depletion of CD4
 
1
 
 and CD8
 
1
 
 T cells from the mice did not diminish the abil-
ity of 
 
a
 
-GalCer to trigger the disappearance of HBV from the liver, indicating that conven-
tional T cells were not downstream mediators of this effect. Finally, the antiviral effect of
 
a
 
-GalCer was inhibited in mice that are genetically deficient for either IFN-
 
g
 
 or the IFN-
 
a
 
/
 
b
 
receptor, indicating that most of the antiviral activity of 
 
a
 
-GalCer is mediated by these cyto-
kines. Based on these results, we conclude that 
 
a
 
-GalCer inhibits HBV replication by directly
activating NKT cells and by secondarily activating NK cells to secrete antiviral cytokines in the
liver. In view of these findings, we suggest that, if activated, the innate immune response, like
the adaptive immune response, has the potential to control viral replication during natural
HBV infection. In addition, the data suggest that therapeutic activation of NKT cells may rep-
resent a new strategy for the treatment of chronic HBV infection.
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Introduction
 
NK T (NKT)
 
1
 
 cells are a subset of CD4
 
1
 
CD8
 
2
 
 or
CD4
 
2
 
CD8
 
2
 
 T cells that express markers associated with
NK cells (NK1.1 antigen and LY49 receptors), exhibit an
activated phenotype (CD44
 
high
 
Ly6C
 
high
 
IL-2R
 
b
 
high
 
), and
display a restricted TCR repertoire (V
 
a
 
14/V
 
b
 
8 in mice,
V
 
a
 
24/V
 
b
 
11 in humans [1–7]). NKT cells are restricted by
the nonclassical MHC class I–like molecule CD1d, which
is known to be expressed on cells of hematopoietic origin
(dendritic cells, B cells, T cells, and macrophages) as well as
hepatocytes (6, 8, 9). NKT cells have been shown to rec-
ognize glycolipid antigens, such as 
 
a
 
-galactosylceramide
(
 
a
 
-GalCer), a glycolipid isolated from marine sponges that
specifically binds CD1d (9–13). After the interaction of the
 
a
 
-GalCer–CD1d complex with the V
 
a
 
14/V
 
b
 
8 TCR, in-
trahepatic mouse NKT cells become activated (12–14).
NKT cell activation results in (a) rapid production of cy-
tokines such as IL-4 and IFN-
 
g
 
, (b) upregulation of activa-
tion markers such as CD69, (c) cell proliferation, and (d)
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increased cytotoxic capacity (6, 9, 12). Other cells, such as
NK cells and T cells, can become activated after the injec-
tion of 
 
a
 
-GalCer in mice. This process has been shown to
be dependent on the release of IFN-
 
g
 
 from the activated
NKT cells (15–17).
NKT cells are particularly abundant in the liver (4, 6,
18), accounting for 20–30% of intraheptic lymphocytes
(IHLs), and they are thought to play a role in immunity to
intracellular bacteria and parasites (19–21) and certain tu-
mors (22). The possibility that NKT cells play a role in the
control of viral infections has not been carefully examined.
Using a hepatitis B virus (HBV) transgenic mouse model,
we have previously shown that the intrahepatic induction
of IFN-
 
g 
 
inhibits HBV replication in the liver (23, 24) by a
nitric oxide (NO)-dependent pathway (25). We have also
shown that IFN-
 
a
 
/
 
b
 
 produced in the liver of HBV trans-
genic mice during various virus infections or after poly–
inosinic-polycytidylic acid (Poly-I/C) injection inhibits
HBV replication via NO-independent pathways (24, 26,
27). Noncytopathic antiviral mechanisms like these con-
tribute to viral clearance during acute viral hepatitis in
chimpanzees (28), thus confirming the transgenic mouse
studies in a natural infection model.
Based on the abundance of NKT cells in the liver and
their ability to produce antiviral cytokines, it is possible that
activated NKT cells might inhibit viral replication during
HBV infection. To test this hypothesis, in this study we
monitored the ability of 
 
a
 
-GalCer to inhibit HBV replica-
tion in the liver of HBV transgenic mice.
 
Materials and Methods
 
Mice.
 
HBV transgenic mouse lineages 1.3.32 and 1.3.46 used
in this study have been described previously (29). Both lineages of
mice replicate HBV at high levels in the liver and kidney without
any evidence of cytopathology. Lineage 1.3.32 was expanded by
repetitive backcrossing against C57BL/6 parental strain and then
bred one generation against BALB/c mice to produce F1 hybrids
used in this study. Lineage 1.3.46 was initially produced and ex-
panded on an inbred B10D2 background. Transgenic mice were
repetitively backcrossed against mice genetically deficient for
 
IFN-
 
g
 
 (IFN-
 
g
 
2
 
/
 
2
 
 [30]), the IFN-
 
a
 
/
 
b
 
R (IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
 [31]),
the TNF-
 
a
 
p55R (TNF-
 
a
 
R
 
2
 
/
 
2
 
 [32]), or inducible NO synthase
(iNOS [iNOS
 
2
 
/
 
2
 
]; reference 33), exactly as described (24, 25).
The knockout mice were provided by Drs. Timothy Stewart
(IFN-
 
g
 
2
 
/
 
2
 
) and Michel Aguet (IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
) at Genentech,
Inc., South San Francisco, CA; Dr. Tak Mak (TNF-
 
a
 
R
 
2
 
/
 
2
 
) at
the University of Toronto, Ontario, Canada. The iNOS
 
2
 
/
 
2
 
 mice
were provided by Drs. John Mudgett (Merck Research Laborato-
ries, Rahway, NJ), John MacMicking, and Carl Nathan (both
from Cornell University Medical College, New York, NY). The
genetic background of the original parental lineages of all knock-
out animals was 129/Sv/Ev/ 
 
3
 
 C57BL/6. The IFN-
 
g
 
2
 
/
 
2
 
 mice
were previously backcrossed four to five generations against
BALB/c mice, and the IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
, TNF-
 
a
 
R
 
2
 
/
 
2
 
, and
iNOS
 
2
 
/
 
2
 
 mice were previously backcrossed more than five gen-
erations against C57BL/6 before they were mated with lineage
1.3.46 (inbred B10D2). F1 progeny were interbred to yield hepa-
titis B e antigen–positive (HBeAg; determined by using a com-
mercially available kit from Abbott Laboratories) F2 progeny that
were either homozygous or heterozygous for the null mutation.
To deplete CD4
 
1
 
 and CD8
 
1
 
 T cells, mice were injected intrave-
nously with 2 mg of rat anti–mouse CD4 (YTS191.1) and rat
anti–mouse CD8 (YTS169.4) monoclonal antibodies provided by
Dr. Rolf Zinkernagel (University Hospital of Zurich, Zurich,
Switzerland [34]) 3 and 1 d before 
 
a
 
-GalCer injection. Efficacy
of treatment was monitored by FACScan™ (Becton Dickinson).
In all experiments, the mice were matched for age (8 wk), sex
(male), and HBeAg levels in their serum before experimental ma-
nipulations. All animals were housed in pathogen-free rooms un-
der strict barrier conditions.
 
a
 
-GalCer.
 
The glycolipid 
 
a
 
-GalCer was originally isolated as
a natural product from marine sponges (10, 11). 
 
a
 
-GalCer was
diluted in PBS from a 10 
 
m
 
g/ml stock solution in DMSO. The
glycolipid control 
 
a
 
-mannosylceramide (
 
a
 
-ManCer) was also di-
luted in PBS from a 10 
 
m
 
g/ml stock solution in DMSO (12).
 
Mice were injected intravenously once with varying doses of 
 
a
 
-Gal-
 
Cer or 
 
a
 
-ManCer, and they were killed at various time points there-
after. Their livers were harvested for histological analyses, or they
were snap frozen in liquid nitrogen and stored at 
 
2
 
80
 
8
 
C for sub-
 
sequent molecular analyses (see below). Control animals were also
injected intravenously with either saline (NaCl) or the vehicle alone
(DMSO diluted in PBS).
 
Tissue DNA and RNA Analyses.
 
Frozen livers (left lobe)
were mechanically pulverized under liquid nitrogen, and total ge-
nomic DNA and RNA were isolated for Southern blot (SB) and
Northern blot (NB) analyses exactly as described previously (29).
Nylon membranes were analyzed for HBV DNA, HBV RNA,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and 2
 
9
 
5
 
9
 
-
oligoadenylate synthetase (2
 
9
 
5
 
9
 
-OAS) as described elsewhere
(26). Quantitation of iNOS, cytokine, T cell, and macrophage
marker mRNAs was performed by RNase protection assay
(RPA) exactly as described previously (23–25). The relative
abundance of HBV DNA molecules was quantitated by phosphor
imaging analysis, using the Optiquant™ image analysis software
(Packard Instrument Co.).
 
Biochemical and Histological Analyses.
 
The extent of hepatocel-
lular injury was monitored by measuring serum alanine ami-
notransferase (sALT) activity at multiple time points after treat-
ment. sALT activity was measured in a Paramax chemical
analyzer (Baxter Diagnostics, Inc.) exactly as described previously
(23). For histological analysis, liver was fixed in 10% zinc-buffered
formalin (Anatech), embedded in paraffin, sectioned (3 
 
m
 
m), and
stained with hematoxylin and eosin (23).
Lymphomononuclear Cell Preparation. Single-cell suspensions were
prepared from liver that was perfused with PBS via the inferior
vena cava and pressed through a 70-mm Cell Strainer (Becton
Dickinson). Total liver cells were digested with 10 ml of RPMI
1640 (Life Technologies) containing 0.02% (wt/vol) collagenase
IV (Sigma-Aldrich) and 0.002% (wt/vol) DNase I (Sigma-Aldrich)
for 40 min at 378C. Cells were washed with RPMI 1640 and
then underlaid with 24% (wt/vol) metrizamide (Sigma-Aldrich)
in PBS. After centrifugation for 20 min at 1,500 g, IHLs were iso-
lated at the interface. RBCs were lysed by lysing buffer (0.15 M
NH4Cl, 10.0 mM KHCO3, and 0.1 mM Na2EDTA at pH 7.2).
The cells were washed once with RPMI 1640 and used for fur-
ther analysis.
Flow Cytometry. Single-cell suspensions of IHLs or PBMCs
were washed in PBS (containing 1% BSA and 0.02% sodium
azide), and incubated for 20 min on ice with culture supernatant
from the hybridoma cell line 2.4G2 (American Type Culture
Collection) to block Fc receptors. The cells were surface stained
with fluorochrome-conjugated monoclonal antibody for 20 min923 Kakimi et al.
on ice. The following antibodies were used: anti-CD3 (clone
17A2), anti-CD4 (clone GK1.5), anti–mouse CD8a (clone 53-
6.7), anti-CD69 (clone H1.2F3), and anti-NK1.1 (clone PK136;
all from BD PharMingen). Samples were acquired on a FAC-
Scan™ flow cytometer, and the data were analyzed using
CELLQuest™ software (Becton Dickinson).
Results
a-GalCer Specifically Inhibits HBV Replication. To exam-
ine the antiviral activity of a-GalCer in HBV transgenic
mice, four age- (8–10 wk), sex- (male), and serum HBeAg–
matched transgenic mice from lineage 1.3.32 were injected
intravenously with 2 mg of a-GalCer and killed 24 h later.
Total hepatic DNA was analyzed for HBV DNA by SB.
Total hepatic RNA was analyzed by NB for the expression
of 2959-OAS (a marker of IFN-a/b induction) and GAPDH.
Total hepatic RNA was also analyzed by RPA for the ex-
pression of iNOS and various cytokines. The results were
compared with those observed in mice that were injected
intravenously either with the vehicle alone (10% DMSO in
PBS) or with 2 mg of a-ManCer, a glycolipid control that
has no ability to activate NKT cells (12).
As shown in Fig. 1 for two representative mice per
group, injection of a-GalCer resulted in a profound inhibi-
tion of most HBV replicative intermediates (z10-fold, as
measured by phosphor imaging analysis, not shown), in-
cluding the single stranded (SS) DNA forms, which com-
pletely disappeared from the liver of these animals by day 1.
The more mature high molecular weight forms, such as the
relaxed circular (RC) double stranded DNA forms, re-
mained detectable, albeit at levels that were lower than
those detected in control mice (Fig. 1). This antiviral effect
was associated with the intrahepatic induction of the
mRNA for 2959-OAS, iNOS, TNF-a, and IFN-g (Fig. 1).
IL-4 was also induced in these animals, although to a much
lesser extent (the intensity of the band for IL-4 corresponds
to a much longer exposure than that for IFN-g; see legend
to Fig. 1 for more details). Concomitant expression of
IFN-g and IL-4 suggests that NKT cells were activated in
these livers, since both cytokines are known to be pro-
duced by these cells after a-GalCer–dependent activation
(13). Other cytokines (TNF-b, IL-5, IL1-a, IL-2, IL-6,
IL-1b, and IL-3) were also analyzed in this assay (Fig. 1).
The messages for these cytokines were at most minimally
induced in the liver of a-GalCer–injected mice in this and
follow-up experiments. Thus, these messages are not
shown in the following figures (see below). Importantly,
HBV replication was not suppressed in the liver of mice
that received either DMSO or a-ManCer, in keeping with
the failure of these agents to induce cytokines in the liver
(Fig. 1). These results strongly suggest that a-GalCer in-
hibits viral replication by activating NKT cells to produce
antiviral cytokines.
a-GalCer–dependent Inhibition of HBV Replication: Dose
Response. To determine the minimum dose of a-GalCer
required to inhibit HBV replication in the transgenic mice,
groups (3 mice per group) of age- (8–10 wk), sex- (male),
and serum HBeAg–matched transgenic mice from lineage
1.3.32 were injected intravenously with varying doses of
a-GalCer, and killed on day 1. Results were compared with
those observed in livers pooled from 10 age-, sex-, and se-
rum HBeAg–matched transgenic littermates injected with
saline (NaCl).
As shown in Fig. 2 for two representative mice per
group, HBV DNA replication was profoundly inhibited in
the liver of the animals that received either 1 ng or 100 pg
of a-GalCer, coincident with the induction of 2959-OAS,
iNOS, IFN-g, and TNF-a mRNA in these livers. HBV
replication was also inhibited (albeit not completely) in the
liver of mice that received 10 pg of a-GalCer and this co-
incided with lower degrees of induction of 2959-OAS and
Figure 1. a-GalCer specifically inhibits HBV replication. Age-, sex-,
and serum HBeAg–matched lineage 1.3.32 HBV transgenic mice were
injected intravenously with 2 mg of a-GalCer, a-ManCer, or vehicle
(DMSO), and mice were killed 1 d after injection. Results were com-
pared with those observed in livers pooled from 10 age-, sex-, and serum
HBeAg–matched, saline-injected transgenic controls (NaCl). Total he-
patic DNA was analyzed for HBV DNA by SB analysis. All DNA samples
were RNase treated before quantitation and gel electrophoresis. Bands
corresponding to the integrated transgene, RC double stranded HBV
DNA, and SS linear HBV DNA replicative forms are indicated. The inte-
grated transgene can be used to normalize the amount of DNA bound to
the membrane. The filter was hybridized with a 32P-labeled HBV-specific
DNA probe. Total hepatic RNA was analyzed for 2959-OAS and
GAPDH transcripts by NB analysis and for iNOS and cytokine transcripts
by RPA, as indicated. Note that all cytokine mRNAs were analyzed in
the same RPA. However, the intensity of the indicated band for IL-4
corresponds to an autoradiographic exposure of 18 d, whereas the inten-
sity of the bands for all other cytokines corresponds to a 2-d exposure.
The mRNA encoding the ribosomal protein L32 was used to normalize
the amount of RNA loaded in each lane of the RPA assay.924 Activated NKT Cells Inhibit HBV Replication
iNOS mRNAs. Finally, no reduction of HBV replication
and no induction of cytokine or NO mRNAs was ob-
served at doses of a-GalCer of 1 pg or less (Fig. 2). All to-
gether, these results indicate that the minimum dose of
a-GalCer that exerts maximum antiviral activity is between
100 and 10 pg/mouse.
a-GalCer–dependent Inhibition of HBV Replication: Time
Course. To examine the kinetics and duration of the anti-
viral effect of a-GalCer, groups (three mice per group) of
age- (8–10 wk), sex- (male), and serum HBeAg–matched
transgenic mice from lineage 1.3.32 were injected intrave-
nously with 10 ng of a-GalCer and killed at various time
points thereafter. To evaluate the magnitude and nature of
the intrahepatic inflammatory response in these livers, we
also monitored in these mice the mRNA content of CD8
(expressed by CTLs [35] and dendritic cells [36]), CD4 (ex-
pressed by T helper cells [37], NKT cells [6], and macro-
phages [38]), F480 (expressed mostly by macrophages [38]),
and CD3 (expressed by CTLs, T helper cells [39], and
NKT cells [6]). Histological analysis of the livers was also
performed to document the intrahepatic cellular events in-
duced by a-GalCer injection (see Fig. 4). In addition, IHLs
were also isolated and analyzed by flow cytometry using
lineage-specific monoclonal antibodies (see Fig. 5). The to-
tal number of each cell subset in the liver was calculated
by multiplying the total number of IHLs by the frequency
of the subset in the IHL populations by FACS® analysis.
Importantly, no differences were observed in the intrahe-
patic NKT, NK, and T cell subsets in the HBV transgenic
mice and genetically identical nontransgenic controls (not
shown).
As shown in Fig. 3 for two representative mice per
group, HBV replication was strongly suppressed on day 1
after a-GalCer injection, similar to the results shown in
Figs. 1 and 2. This effect was associated with a strong in-
duction of 2959-OAS, iNOS, IFN-g, and TNF-a mRNA
and with a very little induction of CD8, CD4, and CD3
mRNA (Fig. 3), indicating that very few CD81, CD41,
and CD31 cells were recruited into the liver at this time
point. In keeping with these results, very small and widely
scattered necroinflammatory foci (consisting of a few lym-
phomononuclear cells and rare apoptotic hepatocytes) were
detected in the liver parenchyma of these animals by histo-
logical analysis (Fig. 4 A), and there was a slight (approxi-
mately twofold) increase in the total number of IHLs re-
cruited into the liver (Fig. 5 A) and most of the increase
was accounted by an influx of NK cells (Fig. 5 B). The dis-
proportionate increase of cytokine and iNOS transcripts
(Fig. 3) on day 1 relative to the T cell and macrophage mark-
ers at this time point (Figs. 3 and 5) suggests that a-GalCer
triggered cytokine and NO production in other cell popu-
lations, presumably NKT cells and secondarily NK cells,
neither of which are detectable by RPA in Fig. 3 but are
detectable by FACS® in Fig. 5. Indeed, we demonstrated
that NKT cells were activated on day 1, since a-GalCer in-
jection rapidly reduced the number of NKT cells from 1.1 3
105 to 1.6 3 104 (Fig. 5 A) and the frequency of NKT cells
by .90% on day 1 (Fig. 5 B). This is consistent with NKT
cell activation, since activated NKT cells are known to rap-
idly undergo apoptosis (17, 40). Importantly, as the NKT
cells were disappearing from the liver on day 1, the total
number of intrahepatic NK cells increased from 1.4 3 105
to 5.5 3 105 (Fig. 5 A) and they were all CD691 (not
shown), indicating that, like the NKT cell populations, the
intrahepatic NK cells had become activated in these mice.
Figure 2. a-GalCer–dependent inhibition of HBV replication: dose
response. Age-, sex-, and serum HBeAg–matched lineage 1.3.32 HBV
transgenic mice were injected intravenously with varying doses (as indi-
cated) of a-GalCer and killed on day 1. Total hepatic DNA and RNA
were analyzed as described in the legend to Fig. 1. The sALT activity val-
ues at the time of autopsy are indicated (bottom) for each mouse and ex-
pressed in U/liter. 
Figure 3. a-GalCer–dependent inhibition of HBV replication: time
course. Age-, sex-, and serum HBeAg–matched lineage 1.3.32 HBV
transgenic mice were injected intravenously with 10 ng of a-GalCer and
killed at the indicated time points. Total hepatic DNA and RNA were
analyzed as described in the legend to Fig. 1. The sALT activity values at
the time of autopsy are indicated (bottom) for each mouse and expressed
in U/liter.925 Kakimi et al.
DNA forms reappeared before the mature RC DNA
forms, in keeping with the natural replication cycle of
HBV, and both forms eventually approached preinjection
levels by day 14 (Fig. 3). Consistent with these changes, the
intrahepatic content of 2959-OAS, iNOS, IFN-g, TNF-a,
CD8, CD4, F480, and CD3 mRNA progressively de-
creased, returning almost to preinjection levels by day 14
(Fig. 3). By flow cytometry we showed that the intrahe-
patic inflammatory cell infiltrate subsided considerably on
day 7 (Fig. 5 A) and progressively diminished to baseline by
day 14, at which time no inflammatory foci were detected
in the liver histologically (not shown).
The liver disease in these animals was also monitored
biochemically by measuring sALT. sALT activity was
slightly increased on day 1 (Fig. 3, bottom), suggesting that
the NKT cells and NK cells or their products were mini-
mally cytopathic for the hepatocyte. The sALT activity re-
mained slightly elevated on day 3 and eventually subsided
to normal levels between 5 and 7 d after injection of a-Gal-
Cer. Since the sALT activity was not significantly higher
on day 3 than on day 1 in the face of a large increase in the
number of intrahepatic inflammatory cells at this time
point, it appears that the recruited cells were not highly cy-
totoxic.
Inhibition of HBV Replication by a-GalCer Is T Cell Inde-
pendent. Because we observed a slight increase in CD3,
CD4, and CD8 mRNA in the liver 1 d after a-GalCer in-
jection, at which time HBV replication had been almost
completely abolished (Fig. 3), we determined if the antivi-
ral effect might reflect activation of the conventional T cell
populations. Accordingly, HBV transgenic mice, age- (8–
10 wk), sex- (male), and serum HBeAg–matched trans-
genic mice (three mice per group) from lineage 1.3.32
Figure 4. Histological features of a-GalCer–induced hepatitis in the liver of mice after 10 ng of a-GalCer injection. Liver sections obtained from a-Gal-
Cer–injected mice killed on day 1 (A) or day 3 (B and C) were stained with hematoxylin and eosin as described in Materials and Methods. On day 1, the
liver was mostly cytologically normal except for a few very small and widely scattered necroinflammatory foci consisting of lymphomononuclear cells and
rare apoptotic hepatocytes (arrows; A). On day 3, inflammatory foci became larger and more abundant, consisting of a mixed population of lympho-
mononuclear cells that often displayed granulomatous features (B). In addition, a mixed lymphomononuclear cell infiltrate was also detected in and adja-
cent to the portal tracts at this time point (C). The infiltrate subsided progressively thereafter, returning to baseline by day 14 (not shown).
Collectively, these results reinforce the notion that both
the NKT and NK cell populations were probably the
source of the intrahepatic cytokines detectable in the liver
at that early time point (Fig. 3).
Further analysis (see below) suggested that the NK cell
infiltrate was probably recruited by the activated NKT
cells, since the NK cell content of the liver continued to
rise on day 3 when the NKT cell subset had started to re-
turn to baseline (Fig. 5 B). Indeed, the intrahepatic inflam-
matory infiltrate increased dramatically on day 3 (Fig. 4, A
and B, and Fig. 5 A), reflecting a series of coordinated
events including the recovery of the NKT cell population
(Fig. 5 B), a further influx of NK cells (Fig. 5 B), and a ma-
jor increase in CD41 and CD81 T cells and F4801 mac-
rophages (Fig. 3) in the liver. These results were confirmed
histologically. As shown in Fig. 4, A and B, the inflamma-
tory foci became larger and more abundant at this time
point, consisting of a mixed population of lymphomono-
nuclear cells that often displayed granulomatous features in
the hepatic parenchyma (Fig. 4 B). In addition, a mixed
lymphomononuclear periportal infiltrate was also detected
in the liver at this time point (Fig. 4 C). Despite the ex-
panded inflammatory infiltrate at this time point, the intra-
hepatic cytokine and iNOS transcript signals were either
unchanged or diminished (Fig. 3), suggesting that the cells
that were recruited after day 1 did not significantly amplify
the intrahepatic cytokine content in these animals. None-
theless, HBV replication was further inhibited on day 3
when even the mature forms (RC) eventually disappeared
(Fig. 3), reflecting the continued, although reduced, pro-
duction of cytokines.
As the cytokine content of the liver returned towards
baseline on day 5 and thereafter (Fig. 3), the immature SS926 Activated NKT Cells Inhibit HBV Replication
were treated with rat anti–mouse CD4 and rat anti–mouse
CD8 monoclonal antibodies to deplete these cells before
the injection of a-GalCer. FACS® analysis of the IHLs be-
fore and after depletion revealed that the intrahepatic
CD41 and CD81 T cell populations were reduced to
,1.5% of preinjection levels after antibody treatment,
whereas the number of NKT cells and NK cells were unaf-
fected (Fig. 6, A and B). Mice were then injected intrave-
nously with 1 ng of a-GalCer or saline (NaCl) as control
and killed 24 h later. As shown in Fig. 6 C for two repre-
sentative mice per group, a-GalCer profoundly inhibited
HBV DNA replication in the liver of the animals lacking
CD41 and CD81 cells, suggesting that they did not con-
tribute to the antiviral activity at this time point. This is
consistent with the notion that a-GalCer directly activates
intrahepatic NKT cells which are very abundant in the
normal liver and, furthermore, that the activation products
of the NKT cells trigger the recruitment and activation of
NK cells that, together with the NKT cells, secrete antivi-
ral cytokines that are responsible for the intrahepatic antivi-
ral activity of a-GalCer.
The Antiviral Effect of a-GalCer Is Mediated by IFN-g and
IFN-a/b. To determine the relative contributions of in-
flammatory cytokines and NO to the antiviral effect of a-Gal-
Cer, 1 mg of a-GalCer was injected into HBV transgenic
mice (lineage 1.3.46) that had been crossed with mice that
are genetically deficient for IFN-g (IFN-g2/2 [30]), the
IFN-a/bR (IFN-a/bR2/2 [31]), the TNF-ap55R (TNF-
aR2/2 [32]), or iNOS (iNOS2/2 [33]). Groups (four mice
per group) of age- (8–10 wk), sex- (male), and serum HBeAg–
matched animals that were either heterozygous (1/2) or
homozygous (2/2) for the respective null mutation were
killed on day 1 after a-GalCer injection and their livers
were processed as described above. Results were compared
with those observed in livers pooled from six age-, sex-,
and serum HBeAg–matched transgenic littermates in each
group that were injected with saline (NaCl). It is important
to note that saline-injected IFN-g2/2, IFN-a/bR2/2, and
iNOS2/2 HBV transgenic mice are known to replicate HBV
at higher levels than are observed in control heterozygous
mice or TNF-aR2/2 mice (24, 25; Fig. 7).
As expected, HBV replication was suppressed in all of the
heterozygous control mice (represented by the TNF-aR1/2
mice in Fig. 7), and this coincided with the induction of
Figure 5. IHLs after a-GalCer injection. Age-, sex-, and serum
HBeAg–matched lineage 1.3.32 HBV transgenic mice were injected in-
travenously with 10 ng of a-GalCer and killed at the indicated time
points. IHLs from these animals were isolated and analyzed by flow cy-
tometry. (A) The total number of IHLs was 1.3 3 106 before injection,
2.7 3 106 on day 1, 7.3 3 106 on day 3, 7.0 3 106 on day 5, and 1.8 3
106 on day 7. The number of each cell subset in the liver was calculated
by multiplying the total number of IHLs by the frequency of the subset in
the IHL populations by FACS® analysis. (B) Phenotypic analysis of IHLs
that express NK1.1 or CD3. The numbers indicate the percentage of
NK1.11CD32 (i.e., NK) cells (top left), NK1.11CD31 (i.e., NKT) cells
(top right), and NK1.12CD31 (i.e., classical T) cells (bottom right)
present in the isolated IHL population.
Figure 6. CD4 and CD8 T cell–indepen-
dent inhibition of HBV replication by a-Gal-
Cer. Age-, sex-, and serum HBeAg–matched
lineage 1.3.32 HBV transgenic mice were
injected intravenously with 2 mg of rat anti–
mouse CD4 (YTS191.1) and rat anti–mouse
CD8 (YTS169.4) monoclonal antibodies 3
and 1 d before they received 1 mg of a-Gal-
Cer, and the mice were killed 1 d later. (A
and B) The efficacy of T cell depletion was
checked by CD4 and CD8 staining of IHLs
from the treated and control mice. The num-
bers indicate the percentage of CD41 cells
(bottom right), CD81 cells (top left), and NKT
cells (top right). (C) Total hepatic DNA was
analyzed for HBV DNA by SB analysis as de-
scribed in the legend to Fig. 1.927 Kakimi et al.
2959-OAS, iNOS, IFN-g, and TNF-a mRNAs (Fig. 7).
Similarly, HBV replication was inhibited in the TNF-aR2/2
and the iNOS2/2 mice, concomitant with the induction of
2959-OAS, iNOS (except in the iNOS2/2 mice), IFN-g,
and TNF-a mRNAs. These results indicate that TNF-a
and NO are not required for the antiviral effect of a-Gal-
Cer. In contrast, HBV replication was still easily detectable
in IFN-g2/2 and IFN-a/bR2/2 mice, although it was
slightly reduced (Fig. 7). Since 2959-OAS was induced in
IFN-g2/2 mice (albeit to a lesser extent than in a-GalCer–
injected heterozygous control mice), it is possible that the
residual antiviral activity of a-GalCer was mediated in
IFN-g2/2 animals by IFN-a/b. Reciprocally, since IFN-g
was induced in IFN-a/bR2/2 mice, it is possible that the
residual antiviral activity of a-GalCer in IFN-a/bR2/2 an-
imals was mediated by IFN-g. This is consistent with our
previous reports that these two cytokines activate indepen-
dent antiviral pathways in this model (24, 25).
Discussion
In this study, we demonstrated that a-GalCer inhibits
HBV replication in the liver of HBV transgenic mice. The
antiviral effect of a-GalCer is rapid, profound, and specific,
and is associated with the induction of IFN-g and IFN-a/b
in the liver. Both of these cytokines mediate the antiviral
effect of a-GalCer, since its activity is strongly reduced in
mice that are genetically deficient for either IFN-g or the
IFN-a/bR. Since the induction of IFN-g and IFN-a/b as
well as the inhibition of HBV replication occur before a
significant number of inflammatory cells are recruited into
the organ, it is likely that these cytokines are produced by
cells that reside in the liver, specifically NKT cells that are
known to produce IFN-g very rapidly in response to a-Gal-
Cer (13) and NK cells that are promptly activated by NKT
cells and enhance induction of IFN-g production (16, 17).
Importantly, our results also demonstrate that a-GalCer in-
duces IFN-a/b in the liver, a previously unreported effect
of this glycolipid.
We have previously shown that IFN-g (produced in the
liver by passively transferred HBV-specific CTLs [23]) and
IFN-a/b (produced in the liver after injection of Poly-I/C
or during infection with unrelated hepatotropic viruses)
can inhibit HBV replication by independent pathways (24).
The results reported herein show that similar antiviral
events can be triggered by a-GalCer via its ability to acti-
vate intrahepatic NKT cells. Based on these results, it is
possible that intrahepatic NKT cells could inhibit HBV
replication during natural infection. In keeping with this
hypothesis, we recently showed that HBV DNA largely
disappears from the liver and the blood of acutely infected
chimpanzees concomitant with the appearance of IFN-g,
but before the major influx of CD31 T cells (28), suggest-
ing that IFN-g might have been produced by nonclassical
T cells, perhaps by activated NKT cells that are known to
express low levels of the CD3–TCR complex and/or by
NK cells that are known to be activated by NKT cells. If
this is correct, intrahepatic NKT cells might contribute to
viral clearance if they become activated during HBV infec-
tion.
NKT cells could become activated by direct or indirect
mechanisms. Direct mechanisms could include the specific
recognition of viral or virus-induced antigen via the TCR.
CD1 is known to accommodate highly hydrophobic mole-
cules, such as glycolipids and phospholipids (41–44). HBV
virions and subviral particles contain glycolipids and phos-
pholipids derived from cellular membranes (45) that could
be processed by CD11 cells (professional antigen-present-
ing cells and hepatocytes) and presented to intrahepatic
NKT cells. We doubt that this mechanism is operative dur-
ing natural HBV infection because we did not observe any
difference in the abundance or activation of the NKT cell
populations in the livers of HBV transgenic versus non-
transgenic mice. Other direct mechanisms include the rec-
ognition of putative ligands by non-TCR receptors (such
as the NKR-P1 receptor, which is also present on NK cells
[46, 47]) or the recognition of cells that lack surface expres-
sion of MHC class I molecules (a mechanism that also in-
duces NK cell activation [46, 47]). Indirect mechanisms
could include activation of NKT cells by virus-induced cy-
tokines (6, 22). Additional studies will be needed to clarify
these alternative scenarios.
NKT cells are resident IHLs, accounting for 20–30% of
IHLs (4, 6, 18); they have a limited TCR repertoire
Figure 7. The antiviral effect of a-GalCer is partially mediated by
IFN-g and IFN-a/b. Age-, sex-, and serum HBeAg–matched lineage
1.3.46 HBV transgenic mice that were either heterozygous (1/2) or ho-
mozygous (2/2) for the IFN-g, the IFN-a/bR, the TNF-ap55R, or
iNOS were injected with 1 mg of a-GalCer and killed 1 d later. Total he-
patic DNA was analyzed for HBV DNA by SB analysis. All DNA samples
were RNase treated before quantitation and gel electrophoresis. Bands
corresponding to the integrated transgene, RC double stranded HBV
DNA, and SS linear HBV DNA replicative forms are indicated. The inte-
grated transgene can be used to normalize the amount of DNA bound to
the membrane. The filter was hybridized with a 32P-labeled HBV-specific
DNA probe. Total hepatic RNA was analyzed for 2959-OAS and
GAPDH transcripts by NB analysis and for iNOS and cytokine transcripts
by RPA, as indicated. The mRNA encoding the ribosomal protein L32
was used to normalize the amount of RNA loaded in each lane of the
RPA assay. Results were compared with those observed in livers pooled
from six age-, sex-, and serum HBeAg–matched transgenic littermates in
each group that were injected with saline (NaCl).928 Activated NKT Cells Inhibit HBV Replication
(Va14/Vb8 in mice, Va24/Vb11 in humans); and they are
restricted by the nonclassical, nonpolymorphic MHC class
I–like molecule CD1d. The pertinence of these observa-
tions for the treatment of chronic HBV infection derives
from the fact that, because of their abundance in the liver,
NKT cells do not need to be recruited in order to exert
their antiviral effect. Furthermore, because of their limited
repertoire, if provided with the appropriate ligand (e.g.,
a-GalCer) NKT cells can be activated very efficiently in
individuals irrespective of their classical MHC class I haplo-
type. This offers a major advantage over antigen-specific im-
munotherapy for chronic HBV infection since it eliminates
the need for priming and expansion of antigen-specific effec-
tor cells and recruitment of these effector cells into the liver.
Furthermore, attempts to therapeutically induce HBV anti-
gen–specific T cell responses in chronically HBV-infected
patients (48) have not been very successful thus far, proba-
bly because of neonatal and/or peripheral tolerance; we
have had the same experience in HBV transgenic mice
(49). In contrast, since they probably do not recognize viral
peptide antigens, NKT cells are not likely to be deleted in
chronically infected patients (50, 51), just as they were not
in the HBV transgenic mice in this study (not shown). This
creates the unique opportunity to use pharmacological ap-
proaches to activate the resident intrahepatic NKT cell
population and, secondarily, the intrahepatic NK cell popu-
lation, thereby rapidly and efficiently enhancing the pro-
duction of potentially curative antiviral cytokines in the
liver of infected patients in a quantitatively and temporally
controllable manner. Thus, it may be possible to harness the
potentially curative antiviral potential of the innate immune
response to compensate for the apparent failure of the adap-
tive immune response in chronically infected patients.
In conclusion, this study demonstrates that a-GalCer ac-
tivates intrahepatic NKT cells to secrete antiviral cytokines
(IFN-g and IFN-a/b) in the liver. The rapid and strong
induction of these cytokines may reflect the relative abun-
dance of NKT cells in the liver (4, 6, 18), all of which can
be simultaneously activated by the glycolipid. Based on
these results, it is conceivable that NKT cells may play a
hitherto unsuspected role in the immunobiology of HBV
infection. In addition, the results suggest that therapeutic
activation of intrahepatic NKT cells may be able to termi-
nate chronic HBV infection.
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